Last edition
News about "Cardiac Myosin Inhibitor (CMI)"
Bristol Myers Squibb Secures FDA Priority Review for Camzyos
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s supplemental New Drug Application (NDA) for Priority Review (PR) of Camzyos (mavacamten) to treat adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Cardiac Myosin Inhibitor (CMI) | 02/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members